Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 11/20 | 0.55 |
| ▸ | PPARA | Q07869 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4682002 | 0.90 | FBP1 (0.57) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL6743475 | 0.87 | FBP1 (0.53) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL4678053 | 0.86 | FBP1 (0.58) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL4677347 | 0.82 | FBP1 (0.55) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL16585371 | 0.82 | FBP1 (0.59) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL581322 | 0.81 | TSHR (0.64) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL3585865 | 0.80 | FBP1 (0.60) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL6740635 | 0.80 | FBP1 (0.55) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL7980993 | 0.79 | FBP1 (0.60) | FBP1PPARATSHRABCB11CYP1A2 | |
| SCHEMBL4735992 | 0.79 | FBP1 (0.51) | FBP1PPARATSHRABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790865-B2 | 2-HYDROXY-2-(4-HYDROXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENOXY OR IMINO)-2-METHYLPROPIONIC ACID DERIVATIVE EXCELLENT BETA 3-ADRENOCEPTOR STIMULANTS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| EP-1072583-B1 | 2-METHYLPROPIONIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-6696489-B1 | PHENOLIC AND PHENYLAMINO SUBSTITUENTS; BETA 3-ADRENOCEPTOR AGONISTS; OBESITY, HYPERGLYCEMIA, INTESTINAL HYPERMOTILITY, POLLAKIURIA, URINARY INCONTINENCE, DEPRESSION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| US-20030166719-A1 | 2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)phenoxy or imino)-2-methylpropionic acid derivative excellent beta 3-adrenoceptor stimulants | KISSEI PHARMACEUTICAL CO., LTD. | 2003-09-04 | — | — | US | disclosed |
| EP-1072583-A1 | 2-METHYLPROPIONIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166719-A1 | 2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)phenoxy or imino)-2-methylpropionic acid derivative excellent beta 3-adrenoceptor stimulants | ADRB1, ADRB2, ADRA2A | FBP1 2185/4885PPARA 323/4885TSHR 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.